Omalizumab - Severe eosinophilic asthma
You are here : Home > Formulary Search > Omalizumab - Severe eosinophilic asthma
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Documentation
NICE Technology Appraisal
PAD Profile
ChemicalSubstance :
Omalizumab
Indication :
Severe eosinophilic asthma
Group Name :
Keywords :
Severe allergic asthma
Brand Names Include :
Xolair
Important Information :
Service not currently provided by any Surrey Heartlands Trusts
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1
Other Indications
Below are listed other indications that Omalizumab is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Severe eosinophilic asthma.
Committee Recommendations (1)
01 Apr 13 -
Not Set
This drug / device falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.
Treatment should remain with the specialist (RED) hospital only drug.
GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.
Treatment should remain with the specialist (RED) hospital only drug.
GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.